Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes-Reference-Cited by-同舟云学术

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Published:2020-12-29 Issue:3 Volume:23 Page:664-673
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hallakou‐Bozec Sophie¹,Vial Guillaume²³^ORCID,Kergoat Micheline⁴,Fouqueray Pascale¹,Bolze Sébastien¹,Borel Anne‐Laure²³⁵^ORCID,Fontaine Eric⁶⁷^ORCID,Moller David E.¹^ORCID

Affiliation:

1. Poxel SA Lyon France

2. Université Grenoble Alpes Grenoble France

3. Inserm U 1042, Laboratoire INSERM U1042, Hypoxia PathoPhysiology (HP2) Grenoble France

4. Metabrain Research Maisons‐Alfort France

5. Centre Hospitalier Universitaire Grenoble Alpes, département de Endocrinologie‐diabétologie‐Nutrition, Centre Spécialisé de l'Obésité Grenoble Arc Alpin Grenoble France

6. Université Grenoble Alpes, LBFA Grenoble France

7. Inserm U 1055, LBFA Grenoble France

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14277

Reference90 articles.

1. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients

2. The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy

3. The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy